Medochemie and RIF Innovation Project

Medochemie and the Research and Innovation Foundation (RIF) signed the contract for the innovation project INNOVATE / 0719/0083, which was selected for funding under the program “Development and Promotion of Internationally Competitive Innovative Products and Services by Existing Companies – RESTART 2016-2020”, in Cyprus. Being part of this project, Medochemie will have the opportunity to raise funding from the Foundation in order to manufacture an innovative drug for treating gastrointestinal disorders.


The contract was signed by the Director of Research, Development and Innovation of Medochemie, Dr. Christakis Sergides and the General Director of the Research and Innovation Foundation, Theodoros Loukaidis. As Dr. Sergides stated, the signing of the contract is of utmost importance, as it will significantly improve the quality of people’s life, suffering from severe gastrointestinal disorders. 
Dr. Nikolas Mastroyiannopoulos, Chief Scientist and Chairman of the Board of Directors of the Research and Innovation Foundation, also stated that the innovative activity of Cypriot companies, such as that of Medochemie, is particularly important in the effort to achieve the strategic goal, to make research and innovation as a basis for sustainable development of our country.